SOBERANA, Cuba's COVID-19 Vaccine Candidates: Dagmar García-Rivera PhD.
MEDICC Rev
; 22(4): 10-15, 2020 10.
Article
in English
| MEDLINE | ID: covidwho-995471
ABSTRACT
On August 13, 2020, Cuba's national regulatory agency, the Center for Quality Control of Medicines, Equipment and Medical Devices (CECMED), authorized clinical trials for SOBERANA 01-Cuba's fi rst vaccine candidate and the fi rst from Latin America and the Caribbean. On August 24, parallel Phase I/II double blind, randomized, controlled clinical trials were launched at clinical sites in Havana to evaluate the vaccine's safety and immunogenicity. Analysis of results and development of different formulations are currently under way and Phase III clinical trials are planned for early 2021. At the time of writing, a second vaccine candidate, SOBERANA 02, was in late-stage development and preparing to begin separate trials this fall.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
Country/Region as subject:
Caribbean
/
Cuba
Language:
English
Journal:
MEDICC Rev
Journal subject:
Public Health
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS